SEO Links | Submit Articles » Article Details
Availability of Forest’s Daliresp in Canada Pharmacy Online |
| Date Added: August 02, 2011 10:49:11 AM |
| Author: psm@canadapharmacyonline.com |
| Category: Health |
| Chronic obstructive pulmonary disease (COPD) has been largely underreported and is the third largest killer disease after heart disease and cancer in Canada. FDA recently approved Daliresp, the first selective PDE4 inhibitor for the treatment of COPD. The once-a-day oral tablet works by reducing the risk of exacerbations thereby preventing severe attacks of chronic bronchitis. Daliresp - The One and Only Oral Medication for Chronic Obstructive Pulmonary Disease COPD is a progressive and irreversible lung disease that does not have a cure. People smoking cigarettes run the maximum risk of getting the condition but very few are actually aware of this fact. Sadly, deaths due to COPD are increasing and will continue to increase unless some serious steps are taken to create more awareness among the people, especially smokers. Breathlessness can occur due to ageing or excess weight, which people normally do not give too much importance to in terms of seeking medication or adapting change in lifestyle. However, when a youngster finds it difficult to climb stairs or walk briskly, it could be due to COPD. Early diagnosis of the disease always helps in reducing the frequency of exacerbations and the need for hospitalization. The required change in lifestyle can be adopted. Giving up cigarette smoking can be the first step towards rehabilitation. Introduction of Daliresp has provided people suffering from COPD the oral option to support already existing techniques and equipment to administer medication. Role of Social Organizations in Creating Awareness of COPD It is often noticed that communication between patients and the healthcare system is not complete. This is quite obvious, because many COPD patients experience flare-ups or lung attacks as they are sometimes called. Viral or bacterial infection is said to be the cause, and symptoms tend to increase in time causing increased inflammation and damage to the lungs. The cold weather in Canada makes breathing quite difficult in the winters. COPD Canada and the Family Physicians Airway Group of Canada has highlighted the lack of response among patients and are encouraging prevention and management systems to ensure better screening of COPD. Lung attacks can take place sporadically, and general practitioners need a screening tool following a particular system to be able to probe further into symptoms demonstrated by patients to prevent attacks that last for more than 48 hours. Patients have to be made aware of the danger involved in getting repeated attacks over a period of time. Quality of life and disease progression is bound to be adversely affected, if communication between the healthcare system and patients does not increase. Heart disease and cancer is reducing only because awareness has increased about proper care beyond hospitalization. Social organizations have taken the initiative to create a more structured approach to COPD. Their roles have been identified. The focus will be on providing a healthy and full lifestyle to patients by educating them on how to deal with chronic situations and preventive measures that help avoid lung attacks. Daliresp has already been made available in Canada from the second quarter of 2011. Canada pharmacy online endorses the oral substitute for COPD medication and is offering it to patients across the world at highly subsidized prices through its online pharmacy. |
|
|
